Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Guobang Pharma Ltd. (605507.SS)
CNY15.69
+0.29 (+1.88%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 60, Xingmei Avenue 312500
Xinchang, CN
Xinchang, CN
CEO
Shixue Liao
Website
gbgcn.com
IPO
2021-08-02
ISIN CNE100004NS2
Description
Guobang Pharma Ltd., a Chinese company, specializes in the research, development, manufacturing, and distribution of pharmaceutical products for both human and veterinary use within China. For human healthcare, their offerings encompass active pharmaceutical ingredients (APIs), intermediate compounds related to these APIs, and finished dosage forms. In the animal health sector, they provide veterinary APIs, various additives, and prepared formulations. The company was founded in 1996 and has its headquarters situated in Xinchang, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY15.69
+0.29 (+1.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.22
Float Shares
475.72M
Free Float %
60.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -29.71% | -4.73% | -10.42% | -23.60% | -10.57% | -13.55% | +5.44% | -4.43% | -54.30% | -54.30% | -54.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.69
DCF (Unlevered)
60.96
+288.5%
DCF (Levered)
34.85
+122.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.51
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.7% Q1'26: +5.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+5.7% Q1'26: -23.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.5% Q1'26: +6.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.3% ★ Q1'26: +12.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.5% ★ Q1'26: +8.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.6% ★ Q1'26: -2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.19× ★ Q1'26: 2.45× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
5.72B
est: 5.58B (+2.5%)
|
5.72B
est: 5.58B (+2.5%)
|
5.35B
est: 5.43B (-1.5%)
|
5.89B
est: 5.86B (+0.6%)
|
5.99B
est: 6.26B (-4.3%)
|
6.80B
6.43B – 6.99B
+8.7% YoY
|
7.62B
7.37B – 7.87B
+12.0% YoY
|
8.53B
8.06B – 8.76B
+11.9% YoY
|
| EBITDA |
1.21B
est: 1.24B (-2.1%)
|
1.21B
est: 1.34B (-9.7%)
|
950.43M
est: 1.30B (-27.1%)
|
1.27B
est: 1.41B (-9.7%)
|
1.39B
est: 1.50B (-7.5%)
|
1.63B
1.54B – 1.68B
+8.7% YoY
|
1.83B
1.77B – 1.89B
+12.0% YoY
|
2.05B
1.94B – 2.10B
+11.9% YoY
|
| EBIT |
949.97M
est: 944.20M (+0.6%)
|
949.97M
est: 848.05M (+12.0%)
|
629.30M
est: 825.13M (-23.7%)
|
836.84M
est: 889.37M (-5.9%)
|
914.78M
est: 950.43M (-3.8%)
|
1.03B
977.31M – 1.06B
+8.7% YoY
|
1.16B
1.12B – 1.19B
+12.0% YoY
|
1.29B
1.23B – 1.33B
+11.9% YoY
|
| Net Income |
920.90M
est: 954.66M (-3.5%)
|
920.90M
est: 948.54M (-2.9%)
|
612.46M
est: 659.59M (-7.1%)
|
781.60M
est: 774.10M (+1.0%)
|
820.82M
est: 935.02M (-12.2%)
|
948.72M
888.80M – 1.01B
+1.5% YoY
|
1.09B
983.51M – 1.20B
+15.2% YoY
|
1.32B
1.23B – 1.37B
+20.6% YoY
|
| SGA |
339.93M
est: 345.53M (-1.6%)
|
339.93M
est: 340.45M (-0.2%)
|
365.25M
est: 331.24M (+10.3%)
|
345.57M
est: 357.03M (-3.2%)
|
314.76M
est: 381.55M (-17.5%)
|
414.75M
392.34M – 426.15M
+8.7% YoY
|
464.41M
449.22M – 479.61M
+12.0% YoY
|
519.87M
491.78M – 534.16M
+11.9% YoY
|
| EPS |
1.65
est: 1.71 (-3.5%)
|
1.65
est: 1.71 (-3.5%)
|
1.10
est: 1.19 (-7.5%)
|
1.40
est: 1.42 (-1.4%)
|
1.48
est: 1.67 (-11.4%)
|
1.74
1.60 – 1.82
+4.4% YoY
|
2.03
1.77 – 2.17
+16.6% YoY
|
2.38
2.21 – 2.46
+16.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
836.11M
OE per share TTM
1.51
Owner's Yield
9.86%
Maintenance CapEx ratio
25.02%
Maint CapEx / Avg PPE
63.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 436.8K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 30.9K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.7K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.53M | 0.06% |
| 5 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.01M | 0.05% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 11.8K | 0.10% |
| 7 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.5K | 0.22% |
| 8 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 7.4K | 0.22% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 4.0K | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 1.7K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
228.5K
Shares Outstanding
782.35M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deguang Peng | Board Secretary | — | male |
| Fangfang Lu | Vice President | — | female |
| Ligao Yao | Vice President & Director | — | male |
| Qibin Li | Vice President & Director | — | male |
| Shixue Liao | President & Director | — | male |
| Xing Cheng Shi | CFO & Accounting Supervisor | — | male |
| Yuda Gong | CFO & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 605507.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
